Earlier studies showed that donor T cells that initiated a murine adoptive EAE persisted in the CNS of the recipients throughout the subsequent relapsing cycles. To clarify the functions of the persistent donor T cells in EAE relapsing disease, anti-Thy-1 antibodies were used to deplete these cells. Results showed that such treatment abrogated subsequent relapsing cycles in these animals. In addition, it was evident that a shift in cytokine profile occurred during acute and relapsing disease phases. These results unambiguously support the appropriateness of targeting T cells with specificity for the priming antigen in design of therapeutic approaches for MS.
Introduction
Experimental autoimmune encephalomyelitis (EAE) is one of the most extensively studied autoimmune diseases and serves as an animal model for the human demyelinating disease, multiple sclerosis (MS). The disease is caused by autoimmune inflammation in the central nervous system (CNS) and can be induced in animals by immunization with myelin antigens or by adoptive transfer of myelin antigen-primed donor T cells into naive recipients (Traugott et al., 1985; Mokhtarian et al., 1984) . SJL is a highly susceptible mouse strain that is often used as a prototype of this disease model. After developing an acute phase of the disease, certain mouse strains spontaneously undergo remission. Different mouse strains may recover to different extent. In this laboratory, clinical recovery in SJL mice is often complete such that these mice appear physically normal during remission (Kim and Tse, 1993) . However, these mice are also prone to spontaneous disease relapses and the remitting/relapsing cycles become a recurring feature of the disease. Over the years, while major efforts have been spent elucidating the induction, the antigen specificity and the regulation of the initial phase of acute EAE, relatively little is known about the factors that trigger the subsequent relapsing episodes or the cytokine milieu at each stage of the disease course. In this respect, the nature and antigen specificity of the T cells mediating the recurring attacks are still open questions (McRae et al., 1995; Takacs et al., 1997; Jone et al., 2003; Kroenke and Segal, 2007) . Some studies suggest that the relapsing cycles are triggered by newly primed T cells with specificities for secondary myelin antigens released from the damaged myelin sheath during the previous disease episode (Tuohy et al., 1999; Vanderlugt et al., 2000; Yu et al., 1996) . This conclusion is supported by demonstration of the sequential appearance, during disease relapses, of dominant T cell populations with antigen specificities different from the priming epitopes such that each relapse cycle is associated with a new encephalitogenic epitope (Vanderlugt et al., 2000; Yu et al., 1996) . On the other hand, more recent studies found that mice could still develop relapsing disease even under circumstances that determinant spread had not occurred (Jone et al., 2003) . In addition, it was reported that cytokine responses during disease relapses were directed predominantly against the priming epitope and not the secondary spread epitopes (Kroenke and Segal, 2007) . This debate about the basic mechanism by which diseases relapses are triggered has important consequential implications for designs of therapeutic remedies. If the secondary spread determinants are indeed the triggers, therapy would have to chase a moving target throughout the relapsing cycles (Steinman, 1999; Vanderlugt and Miller, 2002) . A corollary of this tenet is that T cells specific for the priming epitope associated with the initiation of the acute disease are lost along the way and they plays no role in subsequent relapsing attacks. This is a testable concept and this report, using Thy-1 congenic mouse strains, aims at assessing this contention.
In previous studies using Thy-1 allelic markers to track the longterm trafficking of encephalitogenic T cells in the development of relapsing EAE, Skundric et al. (1993 Skundric et al. ( , 1994 reported that donor T cells in an adoptive transfer system remained in the CNS of the recipients Journal of Neuroimmunology 230 (2011) 26-32 
